SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility and downward pressure as investors react to a double miss in its earnings report, fueling intense community debate regarding the company's long-term growth and the impact of its recent strategic shifts. While some shareholders are capitalizing on the depressed price as a buying opportunity, others are expressing deep frustration and loss of confidence in management, creating a contentious atmosphere among those holding the stock versus those anticipating further declines.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending following strong quarterly results that featured record revenue, raised full-year guidance, and significant growth in its enterprise AI pipeline. The community is focused on a potential short squeeze, citing high short interest, limited share availability, and strong institutional interest as catalysts for continued momentum.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending amid extreme volatility as shareholders weigh a significant year-to-date sell-off against hopes for an earnings-driven reversal. While the community remains deeply divided over the CEOs leadership and the impact of competitors like Amazon, many are closely monitoring the stock's performance ahead of its quarterly report, looking for a catalyst to break a long-term downtrend.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is experiencing intense volatility as investors react to the first major share lockup expiry, which has ignited a battle between shorts anticipating a massive sell-off and bulls who are treating the current dip as a buying opportunity. The community remains deeply divided, with many debating whether the stock's long-term growth potential and Terafab developments outweigh the risks posed by potential insider selling and significant share dilution.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is facing extreme volatility after reporting a mixed second quarter, where a slight revenue miss and softer-than-expected guidance triggered a sharp selloff despite strong year-over-year growth. The community is deeply divided, with some investors panic-selling while others view the sudden drop as a significant buying opportunity for a cash-flow-positive company.

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending after reporting record quarterly revenue that exceeded analyst expectations, further fueled by optimistic management commentary regarding the promising performance of its lung cancer pipeline. Investors are actively discussing the company's improved profit margins and operational efficiencies, while simultaneously monitoring potential competitive developments and speculating on future buyout interest.

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Axon Enterprise Inc

Axon Enterprise is experiencing extreme volatility as investors weigh strong demand for its public safety ecosystem and AI-driven growth against heavy insider selling and concerns regarding high valuation multiples. The community remains deeply divided, with some highlighting the stock's role as a long-term SaaS leader while others point to erratic price swings and dilution as signs of a potential ongoing sell-off.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as the stock surges to new 52-week highs, driven by investor confidence in its margin recovery and management's growth guidance. The community is actively debating whether to hold for long-term triple-digit potential or take profits after the recent vertical price appreciation, while some investors monitor the stock for a potential retest of breakout support levels.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is experiencing heightened community interest and price volatility ahead of its upcoming earnings report, with investors weighing the company's aggressive store expansion and strong customer loyalty against concerns regarding its high valuation and margin compression. While bullish traders point to consistent transaction growth and a clear path for footprint expansion, skeptics are actively debating whether these fundamentals can justify the current earnings multiples in a tighter consumer spending environment.

Cardano is a blockchain platform built on academic research that enables smart contracts and decentralized applications while using significantly less energy than traditional cryptocurrencies like Bitcoin.   What sets Cardano apart is its methodical, research-driven approach — every major feature is peer-reviewed by scientists and cryptographers before being added to the network. This careful process aims to create a more secure and stable foundation compared to platforms that prioritize speed over thorough testing. The platform's native cryptocurrency, ADA, is used to send money, pay transaction fees, and participate in network governance.  Cardano uses a proof-of-stake system to process transactions, which works differently from Bitcoin's mining approach. Instead of competing to solve complex puzzles, users can "stake" their ADA — essentially locking it up temporarily — to become validators who verify transactions. The system selects validators based on how much ADA they've staked and for how long, then rewards them with additional ADA for their participation. This approach uses far less energy than traditional mining while keeping the network secure. The platform also features a two-layer design that separates basic payment transactions from smart contract operations, allowing each function to be optimized independently for better performance.   ADA holders can earn staking rewards by locking up their tokens to help secure the network, vote on proposed changes to the platform, and use ADA for international money transfers with lower fees than traditional services.  Cardano was founded in 2017 by Charles Hoskinson, who previously helped create Ethereum. Hoskinson leads Input Output Global (IOG), the technology company that builds and maintains Cardano's core software. The ecosystem operates through three organizations: IOG handles technical development, the Cardano Foundation promotes adoption and standardization, and Emurgo helps businesses integrate blockchain technology into their operations. This structure distributes responsibilities across multiple groups rather than concentrating control in a single entity.   In February 2025, major asset manager Grayscale Investments filed to create an exchange-traded fund (ETF) for Cardano with the U.S. Securities and Exchange Commission, which would allow traditional investors to buy ADA through their regular brokerage accounts without needing to set up cryptocurrency wallets.

Cardano

Cardano is experiencing heightened community engagement as investors debate whether the current price represents a major accumulation opportunity or a long-term decline. Discussions are focused on the impact of upcoming legislative developments, technical price support levels, and the network's long-term utility versus its recent market performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why

XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.

What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing

What to Know About This Fund's New $22 Million Xenon Pharmaceuticals Buy Ahead of an FDA Filing...

Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus

XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.

X4 Pharmaceuticals (XFOR) Reports Q1 Loss, Lags Revenue Estimates

X4 Pharmaceuticals (XFOR) delivered earnings and revenue surprises of +17.95% and -33.14%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Rating of "Buy" from Brokerages

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) have been given a consensus recommendation of "Buy" by the eighteen analysts that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, fifteen have given a bu...

Xenon Pharmaceuticals (XENE) Projected to Post Quarterly Earnings on Monday

Xenon Pharmaceuticals (NASDAQ:XENE) will be releasing its Q1 2026 earnings after the market closes on Monday, May 11. (View Earnings Report at...

Jennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE

Jennison Associates LLC boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 13.8% during the fourth quarter, according to the company in its most recent...

Pictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENE

Pictet Asset Management Holding SA decreased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 50.4% in the fourth quarter, according to its most recent Form 13F...

Xenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of unusually large options trading activity on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the typical daily volume of 165 put options...

Xenon Pharmaceuticals Highlights Strong Phase III Azetukalner Data, Q3 NDA Plans at Bloom Burton Conference

Xenon Pharmaceuticals (NASDAQ:XENE) provided an update on its clinical and pipeline progress at the Bloom Burton conference, with CEO Ian Mortimer highlighting recent Phase III results for lead program azetukalner, plans for regulatory filings, and continued expansion into psychiatry and pain.

Lead...

$XENE Q1 '26 Earnings Results & Recap

Xenon Pharmaceuticals Inc. expects its $1.34B in cash, cash equivalents, and marketable securities to fund operations for at least 12 months and anticipates submitting an azetukalner NDA to the FDA in Q3 2026.

Xenon Pharmaceuticals, Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

XENE Stock Rallies 50% On Epilepsy Trial Data, But One Analyst Thinks Rival Biohaven Still Has ‘Room To Differentiate’

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

XENEXenon Pharmaceuticals Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest XENE News